Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma.
作者信息
Van Oekelen Oliver, Gleason Charles R, Agte Sarita, Srivastava Komal, Beach Katherine F, Aleman Adolfo, Kappes Katerina, Mouhieddine Tarek H, Wang Bo, Chari Ajai, Cordon-Cardo Carlos, Krammer Florian, Jagannath Sundar, Simon Viviana, Wajnberg Ania, Parekh Samir
机构信息
Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Medicine, Hematology, and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
出版信息
Cancer Cell. 2021 Aug 9;39(8):1028-1030. doi: 10.1016/j.ccell.2021.06.014. Epub 2021 Jun 29.
Abstract
摘要
相似文献
1
Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma.
Cancer Cell. 2021 Aug 9;39(8):1028-1030. doi: 10.1016/j.ccell.2021.06.014. Epub 2021 Jun 29.
2
Loss of anti-spike antibodies following mRNA vaccination for COVID-19 among patients with multiple myeloma.
Cancer Rep (Hoboken). 2023 May;6(5):e1803. doi: 10.1002/cnr2.1803. Epub 2023 Mar 9.
3
Response to COVID-19 mRNA vaccination in multiple myeloma is conserved but impaired compared to controls.
J Hematol Oncol. 2021 Oct 13;14(1):166. doi: 10.1186/s13045-021-01183-2.
4
Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response.
Oncoimmunology. 2022 Sep 6;11(1):2120275. doi: 10.1080/2162402X.2022.2120275. eCollection 2022.
5
Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
Lancet Healthy Longev. 2022 Mar;3(3):e166-e175. doi: 10.1016/S2666-7568(22)00012-5. Epub 2022 Feb 23.
6
Cellular mechanisms associated with sub-optimal immune responses to SARS-CoV-2 bivalent booster vaccination in patients with Multiple Myeloma.
EBioMedicine. 2023 Dec;98:104886. doi: 10.1016/j.ebiom.2023.104886. Epub 2023 Nov 22.
7
Post-vaccination SARS-CoV-2 IgG spike antibody responses among clinical and non-clinical healthcare workers at a tertiary facility in Kenya.
PLoS One. 2024 Apr 4;19(4):e0299302. doi: 10.1371/journal.pone.0299302. eCollection 2024.
8
Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies.
J Immunother Cancer. 2022 Jun;10(6). doi: 10.1136/jitc-2022-004766.
9
Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.
Microbiol Spectr. 2022 Apr 27;10(2):e0225221. doi: 10.1128/spectrum.02252-21. Epub 2022 Mar 9.
10
Time of Day of Vaccination Affects SARS-CoV-2 Antibody Responses in an Observational Study of Health Care Workers.
J Biol Rhythms. 2022 Feb;37(1):124-129. doi: 10.1177/07487304211059315. Epub 2021 Dec 4.
引用本文的文献
1
Circulating SARS-CoV-2 spike IgG antibody responses in cancer patients following multiple COVID-19 vaccination boosters.
Front Immunol. 2025 Aug 12;16:1629473. doi: 10.3389/fimmu.2025.1629473. eCollection 2025.
2
Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies.
Blood Cancer J. 2025 Jul 2;15(1):114. doi: 10.1038/s41408-025-01321-w.
3
T-Cell Redirecting Therapies in Multiple Myeloma: Pathogenesis and Management of Toxicities Beyond CRS and ICANS.
Cancers (Basel). 2025 Apr 30;17(9):1514. doi: 10.3390/cancers17091514.
4
Follow-up of humoral and cellular immune responses after the third SARS-CoV-2 vaccine dose in multiple myeloma patients.
Front Immunol. 2025 Feb 18;16:1532947. doi: 10.3389/fimmu.2025.1532947. eCollection 2025.
5
SARS-CoV-2 immune responses in patients with multiple myeloma and lenalidomide maintenance therapy.
Front Immunol. 2024 Dec 18;15:1510942. doi: 10.3389/fimmu.2024.1510942. eCollection 2024.
6
Mucosal SARS-CoV-2 S1 adenovirus-based vaccine elicits robust systemic and mucosal immunity and protects against disease in animals.
mBio. 2025 Jan 8;16(1):e0217024. doi: 10.1128/mbio.02170-24. Epub 2024 Dec 4.
7
Bispecific antibodies in the treatment of multiple myeloma.
Blood Cancer J. 2024 Sep 12;14(1):158. doi: 10.1038/s41408-024-01139-y.
8
Patients with multiple myeloma infected with COVID-19 during autologous stem cell transplantation.
Infect Agent Cancer. 2024 Aug 12;19(1):38. doi: 10.1186/s13027-024-00603-5.
9
Managing and treating COVID-19 in patients with hematological malignancies: a narrative review and expert insights.
Clin Exp Med. 2024 Jun 4;24(1):119. doi: 10.1007/s10238-024-01381-5.
10
Breakthrough Infections in SARS-CoV-2-Vaccinated Multiple Myeloma Patients Improve Cross-Protection against Omicron Variants.
Vaccines (Basel). 2024 May 9;12(5):518. doi: 10.3390/vaccines12050518.
本文引用的文献
1
Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer.
Cancer Cell. 2021 Aug 9;39(8):1091-1098.e2. doi: 10.1016/j.ccell.2021.06.009. Epub 2021 Jun 18.
2
Seroconversion rates following COVID-19 vaccination among patients with cancer.
Cancer Cell. 2021 Aug 9;39(8):1081-1090.e2. doi: 10.1016/j.ccell.2021.06.002. Epub 2021 Jun 5.
3
Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series.
Ann Intern Med. 2021 Sep;174(9):1330-1332. doi: 10.7326/L21-0282. Epub 2021 Jun 15.
4
Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution.
J Hematol Oncol. 2021 May 17;14(1):81. doi: 10.1186/s13045-021-01090-6.
5
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study.
Lancet Oncol. 2021 Jun;22(6):765-778. doi: 10.1016/S1470-2045(21)00213-8. Epub 2021 Apr 27.
6
Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma.
Lancet Haematol. 2021 Jun;8(6):e389-e392. doi: 10.1016/S2352-3026(21)00110-1. Epub 2021 Apr 19.
7
Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose.
Blood. 2021 Jul 1;137(26):3674-3676. doi: 10.1182/blood.2021011904.
8
Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2.
Nat Med. 2021 Jun;27(6):981-984. doi: 10.1038/s41591-021-01325-6. Epub 2021 Apr 1.
9
Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine.
N Engl J Med. 2021 Apr 8;384(14):1372-1374. doi: 10.1056/NEJMc2101667. Epub 2021 Mar 10.
10
A serological assay to detect SARS-CoV-2 seroconversion in humans.
Nat Med. 2020 Jul;26(7):1033-1036. doi: 10.1038/s41591-020-0913-5. Epub 2020 May 12.
Zotero 插件